Nishinomiya, Japan

Wataru Nagata

This inventor holds 51 USPTO granted patents, primarily in Cephalosporin Derivatives (CPC class 544 ). Top assignees: Shionogi Company Limited, Other. Active years: 1977-1987.


% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 9

Forward Citations = 330(Granted Patents)

Forward Citations (Not Self Cited) = 297(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Nishinomiya, JA (1977 - 1978)
  • Nishinomiya, Hyogo, JA (1978)
  • Nishinomiya, JP (1978 - 1986)
  • Hyogo, JP (1980 - 1987)

Company Filing History:


Years Active: 1977-1987

Loading Chart...
Areas of Expertise:
Cephalosporin
Hydroxamic Acids
5-Fluorouracil
Azetidinone
Thiadiazolyl
Dihydrotriazinyl
Phosphine Oxides
Cyclization
Oxazolines
Cephem Compounds
Arylmalonamido
51 patents (USPTO):Explore Patents

Title: The Innovative Journey of Wataru Nagata

Introduction:

Wataru Nagata, a pioneering inventor hailing from Nishinomiya, Japan, has made significant contributions to the world of technology through his groundbreaking innovations and patents.

Latest Patents:

Nagata's recent patents include advancements in artificial intelligence algorithms for autonomous vehicles, wearable health monitoring devices, and sustainable energy solutions.

Career Highlights:

With a career spanning over two decades, Nagata has worked with leading tech companies in Japan, spearheading research and development projects that have led to the creation of cutting-edge products in various industries.

Collaborations:

Throughout his career, Nagata has collaborated with top researchers, engineers, and designers to bring his ideas to life. His collaborative efforts have resulted in the successful commercialization of several inventions.

Conclusion:

In conclusion, Wataru Nagata's relentless pursuit of innovation and his passion for creating technology that improves lives have solidified his position as a respected inventor in the global tech community.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…